Adults with more than a 12-month history of migraines were assigned randomly in a double-blinded study to receive treatment with experimental drug X (10 or 20 mgday) or placebo. The primary efficacy m?

The primary efficacy measure in this study likely assesses the reduction in the frequency or severity of migraine attacks among participants receiving experimental drug X compared to those receiving a placebo. By utilizing a double-blind design, neither the participants nor the researchers know who is receiving the active treatment or the placebo, which helps eliminate bias and ensures that any observed effects can be attributed to the drug itself rather than external factors. The results will inform whether drug X is effective in managing migraines and provide insights into the optimal dosage for achieving the best outcomes.